Brands
Mankind Pharma Q3 FY26 revenue rises 11.5 per cent
MUMBAI: It appears that Mankind Pharma has found the perfect prescription for growth, proving that even in a volatile market, they have the right chemistry to stay ahead. While others might be feeling a bit under the weather, the Delhi-based drugmaker reported a robust 11.5 per cent year-on-year increase in revenue, reaching a healthy Rs 3,567 crore for the third quarter of FY26. It seems that for Mankind, the best way to treat a financial fever is with a steady dose of chronic care and a strategic dash of super-specialty acquisitions.
The domestic market remains the company’s strongest vital sign, contributing a massive 85 per cent of total revenue. Domestic operations brought in Rs 3,046 crore, up 11.1 per cent from the previous year. This growth was largely fuelled by the company’s increasing focus on “chronic” therapies, those long-term medications for conditions like heart disease and diabetes, which now make up 39.3 per cent of their domestic share.
Specifically, the cardiac segment jumped by 16.7 per cent, while anti-diabetes treatments grew by 14.4 per cent. Key brands like the Telmikind family (up ~21 per cent) and Glizid (which crossed the Rs 200 crore mark) are doing the heavy lifting. Even the Consumer Healthcare wing, home to household names like Manforce and Prega News, regained its pulse with a 5.2 per cent growth, reaching Rs 203 crore after a slightly sluggish second quarter.
Mankind isn’t just sticking to the basics; its recent acquisition of BSV (Bharat Serums and Vaccines) is already adding some serious muscle to the portfolio. BSV’s specialty complex products, which deal with high-entry-barrier areas like fertility and critical care, saw strong double-digit growth this quarter.
On the global front, the company’s export business is looking positively radiant. Revenue from international markets climbed 14.1 per cent to Rs 521 crore. In the US alone, Mankind has now launched 48 products, with four new additions in the first nine months of the financial year.
. Ebitda: Reported at Rs 816 crore, though when adjusted for one-time costs like labour code regulations, the “Adjusted EBITDA” stands at a sturdier Rs 923 crore with a margin of 25.9 per cent.
. Profit after tax (PAT): Came in at Rs 414 crore, a 9.5 per cent increase YoY.
. Cash flow: The company maintains a high-octane cash conversion, with Cash Flow from Operations at Rs 2,398 crore for the first nine months of FY26.
. Market standing: Mankind remains the #2 player in the Indian Pharmaceutical Market (IPM) by volume and holds the #1 spot for prescriptions, covering over 5 lakh doctors with a field force of 18,000.
Vice chairman & managing director Rajeev Juneja noted that the company remains “confident of delivering long-term sustainable growth,” anchored by the “four key pillars” of their base business, specialty chronic segments, OTC brands, and the new BSV super-specialty portfolio. With 23 brand families now worth over Rs 100 crore each, Mankind Pharma seems to have found a recovery plan that is both painless and profitable.
Brands
KKR sixes to power EV charger rollout under VIDA campaign
Cricket meets clean mobility as big hits spark India’s charging growth
NEW DELHI: VIDA, the electric mobility arm of Hero MotoCorp, has teamed up with Kolkata Knight Riders to launch a campaign that turns cricketing flair into real-world impact.
Titled ‘6 for 6’, the initiative promises to install a 6kW fast EV charger for every six hit by KKR during the ongoing Indian Premier League season. The idea is simple but powerful, as each big hit on the field contributes directly to expanding India’s fast-charging infrastructure.
The campaign builds on VIDA’s growing network, which already spans over 5,300 fast-charging points across more than 430 cities. With EV adoption gaining pace, the brand is using cricket’s mass appeal to accelerate both awareness and infrastructure growth.
Explaining the thinking behind the move, Hero MotoCorp emerging mobility business unit chief business officer Kausalya Nandakumar said, “Cricket has an incredible ability to unite and inspire millions across the country. With the ‘6 for 6’ campaign, we are turning every big hit on the field into a step towards a cleaner and a more accessible mobility future.”
She added that VIDA’s expanding fast-charging network and removable battery technology are designed to make EV ownership more convenient and practical for everyday users.
From the franchise’s side, the campaign is also about giving on-field moments a larger purpose. Kolkata Knight Riders chief executive officer Venky Mysore said, “The ‘6 for 6’ campaign exemplifies the potential of sport as a platform for meaningful, real-world impact. By linking every six to the expansion of EV charging infrastructure, this partnership transforms fan excitement into tangible progress.”
As part of the rollout, VIDA has introduced co-branded charging stations in KKR’s signature colours, with a flagship installation unveiled alongside team players. The chargers are designed for quick top-ups, powering VIDA scooters from zero to 80 percent in about an hour, while also being positioned along key highways to support longer journeys.
The initiative also taps into VIDA’s removable battery system, which allows users to charge using standard household plug points, adding flexibility to the charging ecosystem.
By blending the thrill of cricket with the urgency of clean mobility, VIDA and KKR have found a neat way to make every six count twice, once on the scoreboard and again on India’s road to an electric future.
